Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Radwa Ahmed Batran, Mai Elmoshneb, Ahmed Salah Hussein, Omar M Hussien, Fady Adel, Reham Elgarhy & Mosaad I Morsi. (2022) Biosimilars: Science, Implications, and Potential Outlooks in the Middle East and Africa. Biologics: Targets and Therapy 16, pages 161-171.
Read now
Read now
Tomasz Grabowski, Jost Leuschner & Shayne Gad. (2022) 4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri® by repeated intravenous infusion to cynomolgus monkeys. Drug and Chemical Toxicology 45:2, pages 499-506.
Read now
Read now
HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong & Laurent Peyrin-Biroulet. (2021) Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. mAbs 13:1.
Read now
Read now
Articles from other publishers (29)
Michael W. Leach & Katherine Hammerman. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology
175
230
.
Venkata Appa Reddy Goli & Arun Butreddy. (2022) Biosimilar monoclonal antibodies: Challenges and approaches towards formulation. Chemico-Biological Interactions 366, pages 110116.
Crossref
Crossref
Pekka Kurki, Hye-Na Kang, Niklas Ekman, Ivana Knezevic, Martina Weise & Elena Wolff-Holz. (2022) Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 36:3, pages 359-371.
Crossref
Crossref
Lauren Mihalcik, Vincent Chow, Monica Ramchandani, Beth Hinkle, Helen J. McBride & Herve Lebrec. (2021) Use of nonclinical toxicity studies to support biosimilar antibody development. Regulatory Toxicology and Pharmacology 122, pages 104912.
Crossref
Crossref
Beverly Ingram, Rebecca S. Lumsden, Adriana Radosavljevic & Christine Kobryn. (2021) Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities. Pharmaceuticals 14:4, pages 306.
Crossref
Crossref
Mark J. Prescott, Carolyn Clark, William E. Dowling & Amy C. Shurtleff. (2021) Opportunities for Refinement of Non-Human Primate Vaccine Studies. Vaccines 9:3, pages 284.
Crossref
Crossref
Izabela Gierach, Jackelyn M. Galiardi, Brian Marshall & David W. Wood. 2021. Remington. Remington
489
547
.
Sahar Awwad, Christin Henein, Nkiruka Ibeanu, Peng T. Khaw & Steve Brocchini. (2020) Preclinical challenges for developing long acting intravitreal medicines. European Journal of Pharmaceutics and Biopharmaceutics 153, pages 130-149.
Crossref
Crossref
Ce Shi, Zong-Ye Gao, Qi-Lei Zhang, Shan-Jing Yao, Nigel K.H. Slater & Dong-Qiang Lin. (2020) Model-based process development of continuous chromatography for antibody capture: A case study with twin-column system. Journal of Chromatography A 1619, pages 460936.
Crossref
Crossref
Mazin Derzi, Ahmed M. Shoieb, Sharon L. Ripp, Gregory L. Finch, Leslie G. Lorello, Shawn P. O'Neil, Zaher Radi, Jameel Syed, Matthew S. Thompson & Michael W. Leach. (2020) Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab. Regulatory Toxicology and Pharmacology 112, pages 104587.
Crossref
Crossref
Parag Pipalava, Ronak Patel, Miten Mehta, Meghana Dahiya, Inderjeet Singh & Vinu Jose. (2019) An update on the animal studies conducted for biosimilar approvals – Regulatory requirement vs actual scenario. Regulatory Toxicology and Pharmacology 107, pages 104415.
Crossref
Crossref
Pier Luigi Zinzani, Martin Dreyling, William Gradishar, Marc Andre, Francisco J. Esteva, Suliman Boulos, Eva González Barca & Giuseppe Curigliano. (2019) Are Biosimilars the Future of Oncology and Haematology?. Drugs 79:15, pages 1609-1624.
Crossref
Crossref
Helen Prior, Thomas Monticello, Virginie Boulifard, Frank R. Brennan & Ian Kimber. (2019) Integration of Consortia Recommendations for Justification of Animal Use Within Current and Future Drug Development Paradigms. International Journal of Toxicology 38:4, pages 319-325.
Crossref
Crossref
Barbara Melosky, David A Reardon, Andrew B Nixon, Janakiraman Subramanian, Angel H Bair & Ira Jacobs. (2018) Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncology 14:24, pages 2507-2520.
Crossref
Crossref
Yelena Y Janjigian, Marco Bissig, Giuseppe Curigliano, Jennifer Coppola & Mark Latymer. (2018) Talking to patients about biosimilars. Future Oncology 14:23, pages 2403-2414.
Crossref
Crossref
Eduardo Cazap, Ira Jacobs, Ali McBride, Robert Popovian & Karol Sikora. (2018) Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust. The Oncologist 23:10, pages 1188-1198.
Crossref
Crossref
Marjorie A. Peraza, Karen E. Rule, Michael H.I. Shiue, Gregory L. Finch, Stéphane Thibault, Paul R. Brown, David W. Clarke & Michael W. Leach. (2018) Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab. Regulatory Toxicology and Pharmacology 95, pages 236-243.
Crossref
Crossref
Anantha Naik Nagappa & Ramesh Basnet. (2018) Biogenerics and biobetters v/s chemical based drugs - comparative discourse. MOJ Bioequivalence & Bioavailability 5:3.
Crossref
Crossref
Hillel P. Cohen, William C. Lamanna & Martin Schiestl. 2018. Biosimilars. Biosimilars
601
628
.
Paul Baldrick. (2017) Pharmacokinetic and toxicology comparator testing of biosimilar drugs – Assessing need. Regulatory Toxicology and Pharmacology 86, pages 386-391.
Crossref
Crossref
MA. Velasco-Velázquez, N. Salinas-Jazmín, E. Hisaki-Itaya, L. Cobos-Puc, W. Xolalpa, G. González, A. Tenorio-Calvo, N. Piña-Lara, LC. Juárez-Bayardo, LF. Flores-Ortiz, E. Medina-Rivero, NO. Pérez & SM. Pérez-Tapia. (2017) Extensive preclinical evaluation of an infliximab biosimilar candidate. European Journal of Pharmaceutical Sciences 102, pages 35-45.
Crossref
Crossref
Lisa M. Sedger, Charani Ranasinghe, Michael F. McDermott & Parisa Asvadi. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.
Paul Declerck, Romano Danesi, Danielle Petersel & Ira Jacobs. (2017) The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs 77:6, pages 671-677.
Crossref
Crossref
Karen De Smet & Leon AGJM van Aerts. 2017. Biosimilar Drug Product Development. Biosimilar Drug Product Development
175
196
.
Helen Prior, Fiona Sewell & Jane Stewart. (2017) Overview of 3Rs opportunities in drug discovery and development using non-human primates. Drug Discovery Today: Disease Models 23, pages 11-16.
Crossref
Crossref
David R Jones. (2016) Looking to the future of organ-on-chip and toxicity assessment: a regulator's opinion. Future Science OA 2:4, pages FSO153.
Crossref
Crossref
Ian A. Clark & Bryce Vissel. (2016) Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. Journal of Neuroinflammation 13:1.
Crossref
Crossref
Fiona Sewell, Joanna Edwards, Helen Prior & Sally Robinson. (2017) Opportunities to Apply the 3Rs in Safety Assessment Programs. ILAR Journal 57:2, pages 234-245.
Crossref
Crossref
Mazin Derzi, Theodore R. Johnson, Ahmed M. Shoieb, Hugh D. Conlon, Penny Sharpe, Andrew Saati, Sarah Koob, Michael W. Bolt, Leslie G. Lorello, Jim McNally, Carol F. Kirchhoff, Teresa A. Smolarek & Michael W. Leach. (2016) Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab). Advances in Therapy 33:11, pages 1964-1982.
Crossref
Crossref